|
Market Closed -
Nasdaq
16:00:00 2026-08-17 EDT
|
5-day change | 1st Jan Change | ||
| 12.78 USD | -4.34% |
|
-14.06% | -26.93% |
Company Valuation: Summit Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,436 | 10,512 | 10,021 | 7,521 | - | - |
| Change | - | 631.97% | -4.67% | -24.95% | - | - |
| Enterprise Value (EV) 1 | 1,436 | 10,512 | 9,493 | 7,047 | 7,319 | 7,093 |
| Change | - | 631.97% | -9.69% | -25.76% | 3.85% | -3.08% |
| P/E | -2.62x | -58.1x | -12.2x | -10.6x | -10.9x | -18.5x |
| PBR | - | - | 20.7x | 37.3x | 377x | 23.5x |
| PEG | - | 0.8x | -0x | 0.7x | 3.52x | 0.5x |
| Capitalization / Revenue | - | - | - | 2,569x | 180x | 18.3x |
| EV / Revenue | - | - | - | 2,407x | 175x | 17.2x |
| EV / EBITDA | - | -96.9x | -11.7x | -12.3x | -13.4x | -22.8x |
| EV / EBIT | - | -58.8x | -11.7x | -10.6x | -10.3x | -15.7x |
| EV / FCF | - | -93.4x | -39.6x | -12.5x | -10.8x | -12.3x |
| FCF Yield | - | -1.07% | -2.52% | -8.01% | -9.27% | -8.13% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.7828 | -0.2452 | -1.066 | -0.8932 | -0.8655 | -0.5101 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 2.927 | 41.79 | 411.8 |
| EBITDA 1 | - | -108.4 | -810.4 | -571.6 | -547 | -311.8 |
| EBIT 1 | - | -178.8 | -810.5 | -666 | -712.4 | -452.6 |
| Net income 1 | -486.2 | -175.1 | -799.5 | -692.2 | -730 | -437.7 |
| Net Debt 1 | - | - | -528.6 | -473.6 | -202.3 | -427.3 |
| Reference price 2 | 2.049 | 14.254 | 12.995 | 9.428 | 9.428 | 9.428 |
| Nbr of stocks (in thousands) | 700,843 | 737,448 | 771,150 | 797,750 | - | - |
| Announcement Date | 2/20/24 | 2/24/25 | 2/23/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.56x | 2407.27x | -12.33x | -.--% | 10.2B | |
| 21.98x | 7.69x | 15.68x | 1.34% | 73.25B | |
| 35.55x | 9.09x | 27.97x | 0.04% | 61.95B | |
| -81.11x | 15.16x | -77.38x | -.--% | 28.02B | |
| 30.63x | 6x | 15.89x | -.--% | 24.15B | |
| -14.36x | 4.96x | -6.48x | -.--% | 23.01B | |
| 53.29x | 19.73x | 39.94x | 0.07% | 18.35B | |
| 26.57x | 5.01x | 16.8x | -.--% | 19.46B | |
| -664.91x | 38.2x | -17593.58x | -.--% | 15.92B | |
| 16.23x | 4.79x | 11.18x | -.--% | 12.96B | |
| Average | -58.67x | 251.79x | -1,756.23x | 0.15% | 28.73B | |
| Weighted average by Cap. | -24.50x | 95.67x | -967.88x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SMMT Stock
- Valuation Summit Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
